Glutamate and the neural basis of the subjective effects of ketamine: A pharmaco-magnetic resonance imaging study

Archives of General Psychiatry

Volumn 65, Issue 2, 2008, Pages 154-164

  Deakin, J F William ^a   Lees, Jane ^a   McKie, Shane ^a   Hallak, Jaime E C ^a,b   Williams, Steve R ^a   Dursun, Serdar M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; KETAMINE; LAMOTRIGINE; SODIUM CHLORIDE;

ADULT; ARTICLE; BEHAVIOR; BLOOD OXYGENATION; BRIEF PSYCHIATRIC RATING SCALE; CINGULATE GYRUS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DISSOCIATION; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; FRONTAL CORTEX; HUMAN; HUMAN EXPERIMENT; MALE; NERVE CELL; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBITAL CORTEX; OUTCOME ASSESSMENT; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; TEMPORAL CORTEX; THALAMUS; UNITED KINGDOM;

ADULT; ANTICONVULSANTS; AWARENESS; BRAIN; BRIEF PSYCHIATRIC RATING SCALE; CROSS-OVER STUDIES; DISSOCIATIVE DISORDERS; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FRONTAL LOBE; GLUTAMIC ACID; GYRUS CINGULI; HUMANS; IMAGE ENHANCEMENT; IMAGE PROCESSING, COMPUTER-ASSISTED; INFUSIONS, INTRAVENOUS; KETAMINE; MAGNETIC RESONANCE IMAGING; MALE; OXYGEN; PREMEDICATION; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTORS, N-METHYL-D-ASPARTATE; STATISTICS AS TOPIC; TRIAZINES;

EID: 38949173198     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2007.37     Document Type: Article

References (61)

1. Newcomer JW, Farber N, Jevtovic-Todorovic V, Selke G, Melson A, Hershey T, Craft S, Olney J. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology. 1999;20(2):106-118.
2. Curran HV, Morgan C. Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction. 2000;95(4):575-590.
3. Hetem LAB, Danion JM, Diemunsch P, Brandt C. Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacology (Berl). 2000;152(3):283-288.
4. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanaesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 1995;13(1):9-19.
5. Lahti AC, Weiler MA, Michaelidis T, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology. 2001;25(4):455-467.
6. Adler CM, Malhotra A, Elman I, Goldberg T, Egan M, Pickar D, Breier A. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry. 1999;156(10):1646- 1649.
7. Pomarol-Clotet E, Honey GD, Murray GK, Corlett PR, Absalom AR, Lee M, McKenna PJ, Bullmore ET, Fletcher PC. Psychological effects of ketamine in healthy volunteers: phenomenological study. Br J Psychiatry. 2006;189:173-179.
8. Olney JW, Farber N. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995;52(12):998-1007.
9. Takahata R, Moghaddam B. Target-specific glutamatergic regulation of dopamine neurons in the ventral tegmental area. J Neurochem. 2000;75(4):1775-1778.
10. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998;281(5381):1349-1352.
11. Anand A, Charney D, Oren D, Berman R, Hu X, Cappiello A, Krystal J. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutaminergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry. 2000;57(3):270-276.
12. Large CH, Webster EL, Goff DC. The potential role of lamotrigine in schizophrenia. Psychopharmacology (Berl). 2005;181(3):415-436.
13. Breier A, Malhotra A, Pinals D, Weisenfeld N, Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry. 1997;154(6):805-811.
14. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport. 1995;6(6):869-872.
15. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol. 1997;7(1):9-24.
16. Breiter HC, Gollub RL, Weisskoff RM, Kennedy DN, Makris N, Berke JD, Goodman JM, Kantor HL, Gastfriend DR, Riorden JP, Mathew RT, Rosen BR, Hyman SE. Acute effects of cocaine on human brain activity and emotion. Neuron. 1997;19(3):591-611.
17. Stein EA, Pankiewicz J, Harsch HH, Cho JK, Fuller SA, Hoffmann RG, Hawkins M, Rao SM, Bandettini PA, Bloom AS. Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. Am J Psychiatry. 1998;155(8):1009-1015.
18. Wise RG, Rogers R, Painter D, Bantick S, Ploghaus A, Williams P, Rapeport G, Tracey I. Combining fMRI with a pharmacokinetic model to determine which brain areas activated by painful stimulation are specifically modulated by remifentanil. Neuroimage. 2002;16(4):999-1014.
19. McKie S, Del-Ben C, Elliott R, Williams S, del Vai N, Anderson I, Deakin JF. Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology (Berl). 2005;180(4):680-686.
20. Del-Ben CM, Deakin JFW, McKie S, Delvai NA, Williams SR, Elliott R, Dolan M, Anderson IM. The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an fMRI study. Neuropsychopharmacology. 2005;30(9):1724-1734.
21. Anderson IM, Clark L, Elliott R, Kulkarni B, Williams SR, Deakin JF. 5-HT(2C) receptor activation by m-chlorophenylpiperazine detected in humans with fMRI. Neuroreport. 2002;13(12):1547-1551.
22. Abel KM, Allin MPG, Kucharska-Pietura K, Andrew C, Williams S, David AS, Phillips ML. Ketamine and fMRI BOLD signal: distinguishing between effects mediated by change in blood flow versus change in cognitive state. Hum Brain Mapp. 2003;18(2):135-145.
23. Honey RA, Honey GD, O'Loughlin C, Sharar SR, Kumaran D, Bullmore ET, Menon DK, Donovan T, Lupson VC, Bisbrown-Chippendale R, Fletcher PC. Acute ketamine administration alters the brain responses to executive demands in a verbal working memory task: an fMRI study. Neuropsychopharmacology. 2004;29(6):1203-1214.
24. Northoff G, Richter A, Bermpohl F, Grimm S, Martin E, Marcar VL, Wahl C, Hell D, Boeker H. NMDA hypofunction in the posterior cingulate as a model for schizophrenia: an exploratory ketamine administration study in fMRI. Schizophr Res. 2005;72(2-3):235-248.
25. Fu CHY, Abel KM, Allin MPG, Gasston D, Costafreda SG, Suckling J, Williams SCR, McGuire PK. Effects of ketamine on prefrontal and striatal regions in an overt verbal fluency task: a functional magnetic resonance imaging study. Psychopharmacology (Berl). 2005;183(1):92-102.
26. Corlett PR, Honey GD, Aitken MR, Dickinson A, Shanks DR, Absalom AR, Lee M, Pomarol-Clotet E, Murray GK, McKenna PJ, Robbins TW, Bullmore ET, Fletcher PC. Frontal responses during learning predict vulnerability to the psychotogenic effects of ketamine: linking cognition, brain activity, and psychosis. Arch Gen Psychiatry. 2006;63(6):611-621.
27. Bremner JD, Krystal J, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress. 1998;11(1):125-136.
28. Talairach J, Tournoux P. Coplanar Stereotactic Atlas of the Human Brain. Stuttgart, Germany: Thieme; 1988.
29. Stark JA, Davies KE, Williams SR, Luckman SM. Functional magnetic resonance imaging and c-Fos mapping in rats following an anoretic dose of m-chlorophenylpiperazine. Neuroimage. 2006;31(3):1228-1237.
30. Bloom AS, Hoffmann RG, Fuller SA, Pankiewicz J, Harsch HH, Stein EA. Determination of drug-induced changes in functional MRI signal using a pharmacokinetic model. Hum Brain Mapp. 1999;8(4):235-244.
31. Deakin JF, Slater P, Simpson MD, Gilchrist AC, Skan WJ, Royston MC, Reynolds GP, Cross AJ. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem. 1989;52(6):1781-1786.
32. Deakin JFW, Simpson MDC. A two-process theory of schizophrenia: evidence from studies in post-mortem brain. J Psychiatr Res. 1997;31(2):277-295.
33. Krystal JH, D'Souza C, Mathalon D, Perry E, Belger A, Hoffmann R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl). 2003;169(3-4):215-233.
34. Théberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J, Neufeld RW, Rogers J, Pavlosky W, Schaefer B, Densmore M, Al-Semaan Y, Williamson PC. Glutamate and glutamine measured with 4.0T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry. 2002;159(11):1944-1946.
35. Tsai G, Passini LA, Slusher BS, Carter R, Baer L, Kleinman JE, Coyle JT. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry. 1995;52(10):829-836.
36. Bonvento G, Sibson N, Pellerin L. Does glutamate image your thoughts? Trends Neurosci. 2002;25(7):359-364.
37. Mantere T, Tupala E, Hall H, Sarkioja T, Rasanen P, Bergstrom K, Callaway J, Tiihonen J. Serotonin transporter distribution and density in the cerebral cortex of alcoholic and nonalcoholic comparison subjects: a whole-hemisphere autoradiography study. Am J Psychiatry. 2002;159(4):599-606.
38. Martin P, Carlsson ML, Hjorth S. Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats. Neuroreport. 1998;9(13):2985-2988.
39. Millan MJ, Brocco M, Gobert A, Joly F, Bervoets K, Rivet JM, Newman-Tancredi A, Audinot V, Maurel S. Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat. Eur J Neurosci. 1999;11(12):4419-4432.
40. Elliott R, Deakin B. Role of the orbitofrontal cortex in reinforcement processing and inhibitory control: evidence from functional magnetic resonance imaging studies in healthy human subjects. Int Rev Neurobiol. 2005;65:89-116.
41. Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, Schwalb JM, Kennedy SH. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45(5):651-660.
42. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-354.
43. Ostroff R, Gonzales M, Sanacora G. Antidepressant effect of ketamine during ECT. Am J Psychiatry. 2005;162(7):1385-1386.
44. Zarate CA Jr, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, Manji HK, Charney DS. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163(1):153-155.
45. Morecraft RJ, Van Hoesen GW. Convergence of limbic input to the cingulate motor cortex in the Rhesus monkey. Brain Res Bull. 1998;45(2):209-232.
46. Northoff G. What catatonia can tell us about "top-down modulation": a neuropsychiatric hypothesis. Behav Brain Sci. 2002;25(5):555-577.
47. Northoff G, Kotter R, Baumgart F, Danos P, Boeker H, Kaulisch T, Schlagenhauf F, Walter H, Heinzel A, Witzel T, Bogerts B. Orbitofrontal cortical dysfunction in akinetic catatonia: a functional magnetic resonance imaging study during negative emotional stimulation. Schizophr Bull. 2004;30(2):405-427.
48. Ochsner KN, Beer JS, Robertson ER, Cooper JC, Gabrieli JDE, Kihsltrom JF, D'Esposito M. The neural correlates of direct and reflected self-knowledge. Neuroimage. 2005;28(4):797-814.
49. Kjaer TW, Nowak M, Kjaer KW, Lou AR, Lou HC. Precuneus-prefrontal activity during awareness of visual verbal stimuli. Conscious Cogn. 2001;10(3):356-365.
50. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci U S A. 2001;98(2):676-682.
51. Tomitaka S, Tomitaka M, Tolliver BK, Sharp FR. Bilateral blockade of NMDA receptors in anterior thalamus by dizocilpine (MK-801) injures pyramidal neurons in rat retrosplenial cortex. Eur J Neurosci. 2000;12(4):1420- 1430.
52. Sharp FR, Tomitaka M, Bernaudin M, Tomitaka S. Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends Neurosci. 2001;24(6):330-334.
53. Aalto S, Ihalainen J, Hirvonen J, Kajander J, Scheinin H, Tanila H, Någren K, Vilkman H, Gustafsson LL, Syvälahti E, Hietala J. Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology (Berl). 2005;182(3):375-383.
54. Haznedar MM, Buchsbaum MS, Hazlett EA, Shihabuddin L, New A, Siever LJ. Cingulate gyrus volume and metabolism in the schizophrenia spectrum. Schizophr Res. 2004;71(2-3):249-262.
55. Morecraft RJ, Cipolloni PB, Stilwell-Morecraft KS, Gedney MT, Pandya DN. Cytoarchitecture and cortical connections of the posterior cingulate and adjacent somatosensory fields in the rhesus monkey. J Comp Neurol. 2004;469(1):37-69.
56. Vogt BA, Vogt L, Laureys S. Cytology and functionally correlated circuits of human posterior cingulate areas. Neuroimage. 2006;29(2):452-466.
57. Silbersweig DA, Stern E, Frith C, Cahill C, Holmes A, Grootoonk S, Seaward J, McKenna P, Chua SE, Schnorr L, Jones T, Frackowiak RSJ. A functional neuroanatomy of hallucinations in schizophrenia. Nature. 1995;378(6553):176-179.
58. Shergill SS, Brammer MJ, Williams SCR, Murray RM, McGuire PK. Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging. Arch Gen Psychiatry. 2000;57(11):1033-1038.
59. Vogt BA, Vogt L. Cytology of human dorsal midcingulate and supplementary motor cortices. J Chem Neuroanat. 2003;26(4):301-309.
60. Lou HC, Luber B, Crupain M, Keenan JP, Nowak M, Kjaer TW, Sackeim HA, Lisanby SH. Parietal cortex and representation of the mental self. Proc Natl Acad Sci U S A. 2004;101(17):6827-6832.
61. Bleuler E. Die Prognose der Dementia praecox (Schizophrenegruppen). Allgemeine Zeitschrift für Psychiatrie. 1908;65:436-464.